Biocon declares ₹0.50 per share final dividend for FY26
- Biocon declares a final dividend of ₹0.50 per equity share for FY26
- Shareholders on record as of July 3, 2026 are eligible for the payout
- The dividend was approved at the AGM held on August 6, 2026
- Electronic remittance of dividends commenced on August 28, 2026
*this image is generated using AI for illustrative purposes only.
Biocon Limited has commenced the electronic remittance of its final dividend for the financial year ending March 31, 2026. The payout was approved by shareholders at the company’s 48th Annual General Meeting held on August 6, 2026.
The dividend amount has been credited to bank accounts linked with registered demat holdings or folio numbers. Shareholders are advised to verify the credit in their respective accounts.
Dividend Details
The final dividend is fixed at ₹0.50 per equity share. This payout applies to shares held by investors on the record date of July 3, 2026. The face value of each equity share remains at ₹5.
| Parameter | Detail |
|---|---|
| Dividend Per Share | ₹0.50 |
| Face Value | ₹5 |
| Record Date | July 3, 2026 |
| Approval Date | August 6, 2026 |
| Remittance Date | August 28, 2026 |
Shareholder Instructions
Investors who have not received the dividend credit should contact KFin Technologies Limited, the company’s Registrar and Share Transfer Agent. Future communications regarding this matter must include the shareholder name and Folio number or DPID and Client ID.
Rajesh U. Shanoy, Company Secretary and Compliance Officer, confirmed the remittance in a filing dated August 28, 2026.
Historical Stock Returns for Biocon
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.74% | -0.34% | -5.77% | +5.46% | +14.74% | +18.58% |
How does Biocon's current dividend yield compare to its historical averages and peer group in the biopharma sector?
Will Biocon maintain this dividend payout ratio in upcoming quarters given the capital-intensive nature of its R&D pipeline?
What impact might this dividend distribution have on Biocon's free cash flow and future investment capacity for new drug developments?
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
